{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:50:43Z","timestamp":1782791443661,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jid.2023.03.1673","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:30:31Z","timestamp":1683271831000},"page":"1868-1871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid"],"prefix":"10.1016","volume":"143","author":[{"given":"Marc","family":"Yale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8957-3655","authenticated-orcid":false,"given":"Rebecca","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isobel","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.03.1673_bib1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.03.1673_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jid.2023.03.1673_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2021.10.034","article-title":"Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study","volume":"86","author":"Joly","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2023.03.1673_bib7","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2023.03.1673_bib8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the Bullous pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J\u00a0Amer Acad Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib11","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2023.03.1673_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clindermatol.2011.03.016","article-title":"Quality of life in patients with bullous dermatoses","volume":"30","author":"Sebaratnam","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jid.2021.09.013","article-title":"Temporal outcomes after rituximab therapy for pemphigus vulgaris","volume":"142","author":"Tovanabutra","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.03.1673_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in Patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:52:40Z","timestamp":1762206760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23019711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0022202X23019711"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.03.1673","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.03.1673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}